8-K: Surrozen Secures $76.4 Million in First Tranche of Private Placement, Announces Second Tranche Contingent on FDA Clearance

Surrozen, Inc. has successfully completed the first tranche of a private placement, raising $76.4 million, with a second tranche of $98.6 million contingent on FDA clearance for its SZN-8141 program.

Summary

• Surrozen, Inc. has entered into a Securities Purchase Agreement for a two-tranche private placement with institutional and accredited investors.
• The first tranche closed on March 26, 2025, raising approximately $76.4 million before fees and expenses.
• The company issued 5,213,415 shares, pre-funded warrants for 1,373,000 shares, and Series E Common Warrants for 3,293,207 shares in the first tranche.
• The purchase price was $11.60 per Share Unit and $11.5999 per Pre-Funded Warrant Unit.
• The second tranche, contingent on FDA clearance for SZN-8141 by October 31, 2026, aims to raise an additional $98.6 million.
• The second closing may not occur prior to six months and one day following the first closing.
• Investors have the option to purchase the second tranche units earlier under certain conditions.
• The company has agreed to file a registration statement for the resale of shares issued in the private placement.
• Outstanding Series C and D common stock warrants were cancelled, and the exercise prices of Series A and B warrants were reduced.
• Tim Kutzkey, Ph.D., was appointed as a Class I director to the company's Board of Directors.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company has secured significant funding, but the reliance on FDA approval for the second tranche introduces some risk. The appointment of a new director is a positive development.

Positives

• The company successfully raised a significant amount of capital ($76.4 million) to fund its operations.
• The potential for an additional $98.6 million in funding upon FDA clearance provides further financial runway.
• The cancellation of Series C and D warrants simplifies the company's capital structure.
• The reduction in exercise prices for Series A and B warrants may incentivize warrant holders to exercise, providing additional capital.
• The appointment of Tim Kutzkey, Ph.D., to the Board of Directors brings valuable experience and expertise.

Negatives

• The second tranche of funding is contingent on FDA clearance, which introduces uncertainty.
• The cancellation of Series C and D warrants may have been at a cost to the company.
• The reduction in exercise prices for Series A and B warrants dilutes existing shareholders.

Risks

• Failure to obtain FDA clearance for SZN-8141 by October 31, 2026, would jeopardize the second tranche of funding.
• The company's reliance on private placements for funding may indicate difficulty accessing traditional capital markets.
• The potential for dilution from the exercise of warrants could negatively impact existing shareholders.
• The company's research collaboration with TCGFB, Inc. involves related party transactions, which could raise conflict of interest concerns.

Future Outlook

The company anticipates a second closing contingent on FDA clearance for SZN-8141 by October 31, 2026, which would provide an additional $98.6 million in funding. The company intends to use the proceeds for the development of SZN-8141 and SZN-8143.

Industry Context

Private placements are a common funding mechanism for biotechnology companies, particularly those in the clinical stage, as they seek to advance their drug development programs. The reliance on FDA milestones for subsequent funding tranches is also a typical arrangement, aligning investor interests with clinical progress.

Comparison to Industry Standards

• Comparable companies such as BioNTech and Moderna have also utilized private placements to fund their research and development activities.
• The size of the private placement is within the range of similar financings for companies with comparable market capitalizations.
• The contingent nature of the second tranche based on FDA approval is a common practice in the biotech industry, similar to milestone-based funding agreements seen with companies like CRISPR Therapeutics and Editas Medicine.
• The terms of the warrants, including exercise prices and expiration dates, are generally consistent with industry standards for private placements in the biotech sector.

Management Changes

Related Party Transactions

• The company entered into a research collaboration agreement with TCGFB, Inc., which is affiliated with The Column Group, LLC, where Dr. Kutzkey is a Managing Partner.
• The company entered into a sublease agreement with Nura Bio, Inc., where Dr. Kutzkey serves as the chairman of the board of directors.

Stakeholder Impact

• Shareholders may experience dilution from the issuance of new shares and warrants.
• Employees benefit from the company's increased financial stability and ability to fund its programs.
• Customers (potential patients) may benefit from the development of new therapies.
• Suppliers and creditors benefit from the company's improved financial position.

Next Steps

• The company will work towards obtaining FDA clearance for SZN-8141 to secure the second tranche of funding.
• The company will file a registration statement for the resale of shares issued in the private placement.
• The company will continue to develop SZN-8141 and SZN-8143.

Key Dates

Keywords

private placement, SZN-8141, warrants, FDA clearance, capital raise, Surrozen, financing, biotech, investment, shares